NeuroWave Systems

Executive Summary

NeuroWave Systems, founded in 2010 and headquartered in Cleveland, Ohio, is a private medical device company focused on developing innovative brain monitoring and drug delivery systems for anesthesia automation. The company leverages state-of-the-art signal processing and control engineering to create devices aimed at improving patient safety and outcomes during surgery. By pioneering automation in anesthesia, NeuroWave seeks to address the critical need for precise, real-time monitoring of brain activity and closed-loop drug administration, which could reduce human error and enhance efficiency in operating rooms worldwide. Despite being in operation for over a decade, NeuroWave remains in a developmental stage with no publicly disclosed funding rounds, products, or regulatory approvals. The company's niche focus on anesthesia automation is promising but faces significant hurdles, including rigorous FDA approval processes and competition from established players. However, the growing demand for advanced neuromonitoring solutions and the potential for partnerships with healthcare systems offer opportunities. The conviction score of 65 reflects the technological promise tempered by the lack of commercial traction and clear milestones.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) Clearance for Closed-Loop Anesthesia Delivery System40% success
• Q2 2026Strategic Partnership with Major Anesthesia Equipment Manufacturer55% success
• Q3 2026Publication of Positive Clinical Trial Data in Peer-Reviewed Journal50% success